Is Healthcare Tech the Next Big Gold Rush in Investment Banking?

Healthcare technology feels like one of the most underrated growth sectors in the market right now. Over the last few years, the industry has moved far beyond traditional hospital systems into AI-driven healthcare platforms, digital therapeutics, remote patient monitoring, wearable ecosystems, and patient engagement software. 

What’s interesting is how HealthTech now sits at the intersection of healthcare and software, making it increasingly attractive for both healthcare-focused and TMT-focused investors. Large hospitals and clinics are investing heavily in patient portal development, AI clinical documentation tools, and telehealth platforms to reduce administrative costs and improve patient experiences. At the same time, PE firms and venture capital investors are aggressively backing healthcare SaaS and digital wellness startups because of their recurring revenue potential and scalability. 

It also seems like preventive healthcare and wearable-driven ecosystems could become massive over the next decade as consumers focus more on long-term wellness rather than reactive treatment. Curious to hear from people working in IB, PE, VC, or healthcare operations, do you think HealthTech eventually becomes one of the largest investment verticals similar to fintech, or is the sector still too fragmented and regulation-heavy for that level of growth?

18 Comments
 
Most Helpful

Honestly, healthcare always gets pitched as “the next big thing,” and while HealthTech has clearly improved (AI, SaaS, wearables), the reality is still slow. Regulation (ofc its different for the US and EU, we are much more punished over here), fragmented buyers and long sales cycles make scaling hard. That’s why it hasn’t had a fintech-style breakout.

My take: it’s a solid long-term growth sector, but more of a slow burn than a takeoff. The next real “rush” might actually be in AI software consolidation across industries, where scaling and roll-ups are just much easier to execute.

 

Agreed with the above, have worked in HealthTech before. Loved it but the 'slow burn' aspect of it can be frustrating at times. A lot of private equity owned HealthTech companies so there is still a lot of upside to get significant exposure as an operator in the space vs. working at many of the struggling public companies (especially those focused on clinical services, such a crowded space).

Hoping to return to some form of HealthTech post consulting. I actively follow sponsor dealflow within healthcare for this reason. Goal is to find a portco role with maybe some equity / milestone incentives. 

I think it will remain fragmented and I do not think outside of AI, I can't imagine it getting even more regulatory heavy (which it already is).

 

It's a common misconception tbh. Very different spaces, biotech being the much harder space to become an expert in. I've gone to conferences where they've had a combination of both when it came to speakers and panels. And I often had to google a lot of stuff to understand the biotech talks vs. healthtech which were far more intuitive.

 

I hope so.  I invested in GE’s healthcare spin off, GEHC, and health care tech stocks have not done well the past two years due to government cuts, tariffs, reduced export growth (especially to China), difficulties getting rare earths and more recently helium (Persian Gulf).  Hit after hit. 

But the innovations are amazing. The need is growing. I’ve had two friends in their 40’s in the past year get diagnosed with cancer (breast, the other had lung - never smoked).  A periodic full body MRI scan would have helped them detect it early.  A $2,000 MRI scan once every 3 years is nothing, if it saves your life. 

Of course there’s advancements in software and AI.  Probably an advantage (a moat) that the big companies like GE, Phillips, Siemens is their sales/marketing organization and relationships with big health systems. 

So, yes, I’m long term bullish.  I think someone said “you can always want more health care” meaning advances in tech will keep finding a willing customer (we all want to live a healthy long life).

Have compassion as well as ambition and you’ll go far in life. I am interested in digital immortality. Check out my blog at digitalimmortality.com
 

Eh, I still question the need for periodic full body MRI scans unless it's clinically indicated. Agree with the moat, have a buddy in a sales/marketing/product facing role at one of the diagnostics company and he got an amazing offer a few years ago post MBA.

I don't invest in any healthtech public companies due to the volatility and I do not think it's a sound investment long-term because of how much innovation happens. So many companies this past year had their valuations destroyed by AI / competitors. Example - Doximity did very well from Q2 '24 to Q1 '26 then tanked.

 

NewIndustryHorizon

Eh, I still question the need for periodic full body MRI scans unless it's clinically indicated. Unnecessary radiation. Agree with the moat, have a buddy in a sales/marketing/product facing role at one of the diagnostics company and he got an amazing offer a few years ago post MBA.

I don't invest in any healthtech public companies due to the volatility and I do not think it's a sound investment long-term because of how much innovation happens. So many companies this past year had their valuations destroyed by AI / competitors. Example - Doximity did very well from Q2 '24 to Q1 '26 then tanked.

What if MRI scans do not expose you to radiation, would you change your mind about using them as a diagnostic every few years?  I’m reading they don’t. 

Have compassion as well as ambition and you’ll go far in life. I am interested in digital immortality. Check out my blog at digitalimmortality.com
 

Why I liked GEHC is because they are already a leader in hardware and have the established sales channels.  And then they are optimizing the AI/software.

I feel like start ups have to either choose 1) hardware or 2) software/AI.  Doing both at the rate of innovation would be taking on too much since they are different expertise.  

Have compassion as well as ambition and you’ll go far in life. I am interested in digital immortality. Check out my blog at digitalimmortality.com
 

Minus culpa quia culpa voluptatem repellendus consectetur. Velit dolorum et possimus deserunt deleniti. Dignissimos temporibus voluptas numquam earum nulla. Dolor quia iure velit omnis non. Molestiae aut architecto facere et corrupti sit hic velit. Inventore et et illum eius.

Career Advancement Opportunities

July 2026 Investment Banking

  • Evercore 01 99.4%
  • Moelis & Company 01 98.9%
  • JPMorgan 01 98.3%
  • Guggenheim Partners 01 97.7%
  • Morgan Stanley 07 97.1%

Overall Employee Satisfaction

July 2026 Investment Banking

  • Moelis & Company No 99.4%
  • Morgan Stanley 02 98.9%
  • Evercore 01 98.3%
  • BMO Capital Markets 12 97.7%
  • Banco Santander 01 97.1%

Professional Growth Opportunities

July 2026 Investment Banking

  • Evercore 01 99.4%
  • Moelis & Company 01 98.9%
  • Morgan Stanley 06 98.3%
  • Goldman Sachs 01 97.7%
  • JPMorgan 01 97.1%

Total Avg Compensation

July 2026 Investment Banking

  • Vice President (15) $434
  • Associates (46) $258
  • 3rd+ Year Analyst (8) $210
  • 2nd Year Analyst (22) $179
  • Intern/Summer Associate (13) $156
  • 1st Year Analyst (79) $150
  • Intern/Summer Analyst (73) $101
notes
16 IB Interviews Notes

“... there’s no excuse to not take advantage of the resources out there available to you. Best value for your $ are the...”

Leaderboard

1
redever's picture
redever
99.2
2
kanon's picture
kanon
99.0
3
Secyh62's picture
Secyh62
99.0
4
BankonBanking's picture
BankonBanking
99.0
5
dosk17's picture
dosk17
98.9
6
Betsy Massar's picture
Betsy Massar
98.9
7
DrApeman's picture
DrApeman
98.9
8
GameTheory's picture
GameTheory
98.9
9
CompBanker's picture
CompBanker
98.9
10
bolo up's picture
bolo up
98.8
success
From 10 rejections to 1 dream investment banking internship

“... I believe it was the single biggest reason why I ended up with an offer...”